Imugene Limited (AU:IMU) has released an update.
Imugene Limited has announced the issuance of over 87 million ordinary shares to fulfill part of the deferred consideration for a licensing agreement with Precision Biosciences Inc. This strategic move, detailed in their recent ASX release, is aimed at bolstering the company’s immuno-oncology portfolio, which includes innovative therapies for cancer treatment. The shares were issued in accordance with legal requirements and the company asserts compliance with all necessary disclosure obligations.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
